Healthcare Business

Why Melinta Therapeutics Shares Are Getting Crushed

Posted: May 24, 2018 at 10:20 am

Melinta Therapeutics Inc. (NASDAQ: MLNT) saw its shares plunge on Thursday after the firm announced that it had priced its secondary offering. Essentially, the firm is looking to raise more ...
Read Full Story »

Why Cara Therapeutics Shares Are Soaring

Posted: May 23, 2018 at 10:50 am

Cara Therapeutics Inc. (NASDAQ: CARA) shares made a solid gain on Wednesday after the firm announced that it has licensed rights to commercialize Korsuva (CR845/difelikefalin) injection for the treatment of ...
Read Full Story »

Esperion Therapeutics Shares Briefly Halted on Late-Stage Cholesterol Trial

Posted: May 23, 2018 at 10:10 am

Esperion Therapeutics Inc. (NASDAQ: ESPR) shares were halted in premarket trading on Wednesday after the firm announced late-stage trial results for its cholesterol drug. Specifically, the Phase 3 study evaluated bempedoic ...
Read Full Story »

Amgen Wins Another FDA Approval

Posted: May 22, 2018 at 11:40 am

Amgen Inc. (NASDAQ: AMGN) shares made a slight gain on Tuesday after it was announced that the U.S. Food and Drug Administration (FDA) approved its treatment of glucocorticoid-induced osteoporosis in ...
Read Full Story »

Dova Pharmaceuticals Slumps Despite FDA Approval

Posted: May 21, 2018 at 12:30 pm

Dova Pharmaceuticals Inc. (NASDAQ: DOVA) shares dropped on Monday following a critical update from the U.S. Food and Drug Administration (FDA) on one of its subsidiaries. Essentially, the agency granted ...
Read Full Story »

Should Nabriva Be Seeing a Better Response for This Positive Trial?

Posted: May 21, 2018 at 10:10 am

Nabriva Therapeutics PLC (NASDAQ: NBRV) watched its shares take a step back on Monday's despite seeing positive results in its late-stage pneumonia trial. The stock was actually up about 17% ...
Read Full Story »

9 Companies Bracing for Big ASCO Reactions

Posted: May 19, 2018 at 8:25 am

This year marks the 54th annual meeting of the American Society of Clinical Oncology (ASCO). Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference (June 1 ...
Read Full Story »

FDA Lists Brand-Name Drugmakers That Obstruct Generic Development

Posted: May 18, 2018 at 9:45 am

All three drugmakers included in the Dow Jones industrial index were on a list of drug companies published Thursday by the U.S. Food and Drug Administration (FDA) alleged to have withheld ...
Read Full Story »

Amgen’s Novel Migraine Treatment Gets Key Approval

Posted: May 18, 2018 at 8:00 am

Amgen Inc. (NASDAQ: AMGN) shares saw a nice bump after the U.S. Food and Drug Administration (FDA) on Thursday approved Aimovig (erenumab), Amgen's preventive treatment of migraine in adults. It ...
Read Full Story »

Why Jounce Shares Are Crumbling Ahead of ASCO

Posted: May 17, 2018 at 10:25 am

Jounce Therapeutics Inc. (NASDAQ: JNCE) watched its shares crumble on Thursday after the firm released data from its midstage cancer trial. This data comes at a pivotal point, not just ...
Read Full Story »

Why Evolus Shares Are Getting Slammed

Posted: May 16, 2018 at 12:25 pm

Evolus Inc. (NASDAQ: EOLS) watched its shares come crashing down on Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) ...
Read Full Story »

Are Abaxis Shareholders Getting Enough in the Buyout?

Posted: May 16, 2018 at 9:50 am

Abaxis Inc. (NASDAQ: ABAX) shares hit an all-time high early on Wednesday after it was announced that Zoetis Inc. (NYSE: ZTS) would be acquiring the firm. The acquisition is expected ...
Read Full Story »

Are Xenon Pharmaceuticals Shares Making a Run?

Posted: May 15, 2018 at 10:10 am

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares saw a handy gain on Tuesday after the firm announced positive data from a couple of its trials. Specifically, Xenon presented data from its ...
Read Full Story »

UBS Makes Big Health Care Swap in Top Performing Q-GARP Portfolio

Posted: May 14, 2018 at 9:55 am

Over the years, we have continued to cover the UBS Quality Growth at a Reasonable Price (Q-GARP) portfolio, and with good reason. The portfolio managers have always focused on high-quality ...
Read Full Story »

Big Biotechs Scare Off Short Sellers

Posted: May 10, 2018 at 10:40 am

The short interest data are out for the most recent settlement date, April 30. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »